Baseline characteristics of large B-cell lymphoma treated with CD19 CAR T cells
| Baseline parameters . | N = 60 (%) . |
|---|---|
| Median age at CAR T cell (range), y | 63 (19.5-85.9) |
| Male:female sex | 42:18 |
| Histopathological diagnosis | |
| De novo diffuse large B-cell lymphoma | 35 (58.3) |
| Transformed indolent lymphoma | 25 (41.7) |
| Stage | |
| 1-2 | 14 (23.3) |
| 3-4 | 38 (63.3) |
| Not available | 8 (13.3) |
| ECOG performance status | |
| 0-1 | 44 (73.3) |
| 2 | 10 (16.7) |
| 3 | 2 (3.3) |
| Not available | 4 (6.7) |
| Median no. of prior treatments (range) | 3 (2-9) |
| Response to prior treatments | |
| Primary refractory disease | 10 (16.7) |
| Relapsed disease | 50 (83.3) |
| Presence of bulky disease | |
| Yes | 9 (15.0) |
| No | 45 (75.0) |
| Not available | 6 (10.0) |
| LDH before lymphodepletion | |
| Normal | 30 (50.0) |
| Elevated | 30 (50.0) |
| History of HCT | |
| Yes | 16 (26.7) |
| No | 44 (73.3) |
| Bridging treatment before CAR T-cell therapy | |
| High-intensity systemic therapy | 23 (38.3) |
| Low-intensity systemic therapy* | 11 (18.3) |
| Radiotherapy* | 5 (8.3) |
| No bridging therapy or systemic corticosteroid | 22 (36.7) |
| Lymphodepletion chemotherapy | |
| Fludarabine/cyclophosphamide | 57 (95.0) |
| Bendamustine | 3 95.0) |
| CAR T-cell product | |
| Axicabtagene ciloleucel | 43 (71.7) |
| Tisagenlecleucel | 17 (28.3) |
| Baseline parameters . | N = 60 (%) . |
|---|---|
| Median age at CAR T cell (range), y | 63 (19.5-85.9) |
| Male:female sex | 42:18 |
| Histopathological diagnosis | |
| De novo diffuse large B-cell lymphoma | 35 (58.3) |
| Transformed indolent lymphoma | 25 (41.7) |
| Stage | |
| 1-2 | 14 (23.3) |
| 3-4 | 38 (63.3) |
| Not available | 8 (13.3) |
| ECOG performance status | |
| 0-1 | 44 (73.3) |
| 2 | 10 (16.7) |
| 3 | 2 (3.3) |
| Not available | 4 (6.7) |
| Median no. of prior treatments (range) | 3 (2-9) |
| Response to prior treatments | |
| Primary refractory disease | 10 (16.7) |
| Relapsed disease | 50 (83.3) |
| Presence of bulky disease | |
| Yes | 9 (15.0) |
| No | 45 (75.0) |
| Not available | 6 (10.0) |
| LDH before lymphodepletion | |
| Normal | 30 (50.0) |
| Elevated | 30 (50.0) |
| History of HCT | |
| Yes | 16 (26.7) |
| No | 44 (73.3) |
| Bridging treatment before CAR T-cell therapy | |
| High-intensity systemic therapy | 23 (38.3) |
| Low-intensity systemic therapy* | 11 (18.3) |
| Radiotherapy* | 5 (8.3) |
| No bridging therapy or systemic corticosteroid | 22 (36.7) |
| Lymphodepletion chemotherapy | |
| Fludarabine/cyclophosphamide | 57 (95.0) |
| Bendamustine | 3 95.0) |
| CAR T-cell product | |
| Axicabtagene ciloleucel | 43 (71.7) |
| Tisagenlecleucel | 17 (28.3) |
One patient received combined treatment modalities.